Today: 7 February 2026
Subscribe
Browse Category

NYSE:PFE News 6 October 2025 - 25 November 2025

PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge

PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge

Pfizer Inc. (NYSE: PFE) is back on many traders’ screens today. As of early afternoon on Tuesday, November 25, 2025, Pfizer shares are trading around $25.65, up roughly 1.7% on the session, after touching an intraday high near $25.96 and a low around $25.24. That puts PFE stock in the middle of its 52‑week range between $20.92 and $27.69, with a market capitalization of roughly $143 billion.Stock Invest+1 Behind the modest move higher lies a busy news backdrop: Below is a detailed look at Pfizer stock today, the latest catalysts, and what they could mean for PFE’s outlook. Pfizer (PFE)
25 November 2025
····
Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Published: November 23, 2025 Pfizer Inc. (NYSE: PFE) heads into the new week with its share price stuck around the mid‑$20s, a near‑7% dividend yield, and a flurry of fresh headlines that could shape the stock’s next move. Over the past few days the pharma giant has closed a multibillion‑dollar obesity acquisition, secured a major new U.S. cancer approval, sold $6 billion in new bonds and agreed to a $41.5 million legal settlement in Texas – while new analysis published today highlights both its long‑term potential and its risks. Reuters+3Pfizer+3Pfizer+3 Below is a roundup of the latest news and analysis
23 November 2025
·····
Pfizer Stock Today, November 22, 2025: 7% Dividend, $6 Billion Bond Sale and New Health Scare Put PFE Back in Focus

Pfizer Stock Today, November 22, 2025: 7% Dividend, $6 Billion Bond Sale and New Health Scare Put PFE Back in Focus

Pfizer stock heads into the weekend trading just above $25, with investors digesting a busy week of news: a strong Q3 earnings beat, a fresh FDA cancer-drug approval, completion of a multi‑billion‑dollar obesity deal, a new $6 billion bond issue – and even a headline‑grabbing bird flu case that once again reminds markets of Pfizer’s role in vaccines and antivirals. Benzinga+3Business Wire+3Pfizer+3 Pfizer stock price today: where PFE stands on November 22, 2025 U.S. markets are closed today (Saturday), so the latest full trading session for Pfizer Inc. (NYSE: PFE) is Friday, November 21, 2025: Data providers like IndMoney and
23 November 2025
·····
Pfizer Stock Today (PFE): mRNA Flu Breakthrough, $6B Metsera Bonds and a 7% Dividend – Nov. 21, 2025

Pfizer Stock Today (PFE): mRNA Flu Breakthrough, $6B Metsera Bonds and a 7% Dividend – Nov. 21, 2025

Pfizer’s share price is back in the spotlight on Friday, November 21, 2025, as investors digest strong Phase 3 flu-vaccine data, a $6 billion bond sale to fund its obesity-drug deal, and ongoing debate around the company’s roughly 7% dividend yield. Pfizer stock price on November 21, 2025 Pfizer (NYSE: PFE) staged a solid rebound in Friday’s regular session: For context, Pfizer’s shares are still down about 8% year-to-date, even as the broader large-cap pharma peer group has gained more than 15%, according to new Zacks analysis. Nasdaq That combination — a beaten-down share price, a high yield and fresh
21 November 2025
·····
Metsera (MTSR) News Today, 21 November 2025: Pfizer’s $10 Billion Buyout, $6 Billion Bond Sale and What It Means for Investors

Metsera (MTSR) News Today, 21 November 2025: Pfizer’s $10 Billion Buyout, $6 Billion Bond Sale and What It Means for Investors

Pfizer has closed its up to $10 billion acquisition of Metsera (MTSR) and raised $6 billion in bonds to help fund the deal. Here’s what today’s developments mean for former Metsera shareholders, Pfizer investors and the future of the obesity drug market. What Happened Today: Pfizer Locks In $6 Billion Bond Financing The main fresh headline for 21 November 2025 is on the financing side, not on Metsera’s standalone stock — because MTSR no longer trades. German market outlet boerse‑global/ad‑hoc‑news reports that Pfizer has successfully raised $6 billion in the U.S. investment‑grade bond market to support the cash portion of
21 November 2025
······
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer Stock Today (Nov. 18, 2025): PFE steadies near $25 as Pfizer launches multi‑tranche bond sale to help fund Metsera deal

Summary Live PFE snapshot (intraday) New today: Pfizer sells debt to fund Metsera Pfizer began marketing a U.S. dollar investment‑grade bond expected to raise at least $5 billion, with the deal structured in as many as seven parts. Early discussions include a 40‑year tranche initially talked around ~125 bps over Treasuries, according to Bloomberg reporting on the transaction. A separate Reuters alert flagged a seven‑part notes offering in a fresh SEC filing, with sizing to be finalized at pricing. Together, the moves point to active balance‑sheet management following the Metsera close. Bloomberg Law+1 Why it matters: reading the financing signal
18 November 2025
·····
Pfizer (PFE) Stock Today, November 17, 2025: Migraine Drug Launch in India, Metsera Deal Closes and New RSV Vaccine Data

Pfizer (PFE) Stock Today, November 17, 2025: Migraine Drug Launch in India, Metsera Deal Closes and New RSV Vaccine Data

Pfizer Inc. (NYSE: PFE) is back in the headlines today with a flurry of developments that span new product launches, obesity-drug M&A, fresh vaccine data and ongoing debate about whether its battered stock is finally a buy. As of this afternoon, Pfizer shares are trading around $25.28, little changed on the day, and still down roughly 55% from their late‑2022 peak, leaving the dividend yield near the 7% level that has attracted income‑focused investors.sharewise.com+1 Below is a breakdown of the key Pfizer news and stock drivers for November 17, 2025. Market snapshot: PFE on November 17, 2025 Short‑term quantitative models
17 November 2025
···
Pfizer Completes $10 Billion Metsera (MTSR) Buyout as Nasdaq Delists Stock Today

Pfizer Completes $10 Billion Metsera (MTSR) Buyout as Nasdaq Delists Stock Today

Metsera Inc. (NASDAQ: MTSR) stops trading today, November 14, 2025, as Pfizer closes its up to $10 billion obesity-drug acquisition. Here’s what Metsera shareholders and obesity-market investors need to know about the deal terms, CVR, delisting, and future milestones. Date: November 14, 2025Ticker: MTSR (Metsera, Inc.) – now being delisted On Friday, November 14, 2025, Metsera, Inc. officially disappears from the Nasdaq tape. Trading in Metsera (NASDAQ: MTSR) has been suspended after Pfizer completed its acquisition of the obesity-focused biotech in a deal valued at up to $10 billion, capping one of the fiercest pharma bidding wars of the year.
14 November 2025
······
Stocks to Watch Today (Nov. 10, 2025): Nvidia Rebounds; Pfizer Clinches Metsera; Novo Nordisk Rises; Rumble Soars on AI Deal; Tyson Foods Guides Higher

Stocks to Watch Today (Nov. 10, 2025): Nvidia Rebounds; Pfizer Clinches Metsera; Novo Nordisk Rises; Rumble Soars on AI Deal; Tyson Foods Guides Higher

Published: November 10, 2025 Key takeaways Market snapshot: AI leads early rebound U.S. index futures moved higher Monday as Senate action over the weekend boosted hopes for a stopgap funding bill to end the record federal shutdown. Nasdaq 100 futures led gains and AI bellwether Nvidia (NASDAQ: NVDA) traded about 3% higher premarket, pacing a broader chip bounce. Reuters Adding to the tone, Nvidia CEO Jensen Huang said over the weekend that demand for the company’s next‑gen Blackwell platform remains “very strong,” underscoring continued wafer needs from TSMC. The remarks come as investors look to AI hardware leaders to reassert
10 November 2025
········
Tariffs Fail to Derail European Stock Rally as Markets Bounce Back

GOOGL, NVDA, PFE, NIO, JOBY: 5 Fast‑Profit Catalysts to Watch Today (Nov. 10, 2025)

Published: November 10, 2025 Key takeaways today Why these five? Today’s market is rewarding near‑term, verifiable catalysts—product cycles (NVDA), M&A (PFE), monthly prints and policy (NIO), certification milestones (JOBY), and AI‑plus‑ads seasonality (GOOGL). That mix aligns with the “fast‑profit” focus highlighted by Traders Union’s latest screen, which zeroes in on GOOGL, NVDA, PFE, NIO and JOBY as names where news flow drives outsized moves. Traders Union Nvidia (NVDA): Blackwell demand, wafer asks, and China stance What changed today: Over the weekend in Taiwan, CEO Jensen Huang said demand for Nvidia’s Blackwell platform remains “very strong,” adding that the company is
10 November 2025
········
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock Soars After Trump’s Drug Deal and Obesity Bet – Is This the Start of a Comeback?

Stock Performance: From Laggard to Late-September Lift For much of 2025, Pfizer’s stock was stuck in a rut – but that changed dramatically as Q4 approached. By late September, PFE had drifted down near multi-year lows around $23, reflecting a post-pandemic hangover. As of Sept 25, the stock was down roughly 9% year-to-date and about 18% below its level one year priorts2.tech. It traded near the bottom of its 52-week range ($20.92 – $30.43), weighed down by steep declines in COVID vaccine and pill sales and general pessimism on its growth prospectsts2.techts2.tech. In fact, Pfizer’s COVID-driven revenues had plummeted from
6 October 2025
·····
1 … 8 9 10

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop